Skip to main content
Fig. 3 | Cancer Imaging

Fig. 3

From: FDG-PET/CT imaging for evaluating durable responses to immune check point inhibitors in patients with advanced cutaneous squamous cell carcinoma

Fig. 3

RECIST1.1 and PERCIST1.0 assessments from time of cemiplimab commencement. This figure highlights the relevant response assessments as well as the most recent RECIST1.1 assessment. CMR, complete metabolic response; SMD, stable metabolic disease; PMD, progressive metabolic disease. CR, complete response; PR, partial response. SD, stable disease. PD, progressive disease

Back to article page

Cancer Imaging

ISSN: 1470-7330

Contact us